FDA Approved First PET Imaging Agent for Glioma

The new agent helps distinguish recurrent brain tumors from treatment effects in patients as young as one month old.

Updated on Oct. 6, 2026 in Cancer

Bold flat-color editorial illustration in navy, cream, and deep red, showing an abstract geometric representation of cellular receptor proteins. — The FDA has approved Pixclara, a new PET imaging agent designed to help clinicians distinguish between brain tumor progression and treatment-related tissue changes. AI Illustration. Upload story photo >

Live Poll

Is now a good time to ask your doctor about new imaging tools for your health?

The FDA approved Pixclara in September 2026 as the first amino acid PET imaging agent for glioma. This radioactive tracer is designed to help clinicians differentiate between true tumor progression and treatment-related changes in both children and adults.

Why it matters

Distinguishing between new tumor growth and damage caused by therapies like radiation remains a complex challenge in neuro-oncology. This tool provides a more reliable method to guide clinical decision-making for brain tumor patients.

Safety data for the agent included 382 total patients, consisting of 371 adults and 11 children. The diagnostic approach shows 88% sensitivity for identifying tumor progression and 78% specificity for detecting treatment-related changes.

The players

Food and Drug Administration

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and drugs.

The details

Pixclara, a modified version of the amino acid tyrosine, is injected intravenously before a PET scan to identify glioma cells. The tracer targets LAT1 and LAT2 transporters located on the surface of glioma cells, which absorb the radioactive substance for imaging.

September 14, 2026: The FDA approved the imaging agent.

The Big Picture

The FDA approval follows the long-standing clinical use of FET-PET in Europe. This marks the first time this specific type of amino acid PET imaging technology has been formally authorized by U.S. regulators.

Patients with gliomas may see improved accuracy in follow-up imaging, which can help physicians avoid unnecessary or delayed interventions. Headache was the most frequently reported side effect for those receiving the injection during clinical evaluations.

The takeaway

This approval provides a new diagnostic resource for the oncology community to manage complex brain tumor cases. Patients and their families should discuss with their neuro-oncologists whether this imaging agent is appropriate for their specific clinical circumstances.